NovaMedica Innoteh

NovaMedica Innotech (a 100% subsidiary of the company NovaMedica"") is Russian pharmaceutical R&D a center opened in April 2017 on the territory of the SEZ. Technopolice Moscow

The technology center specializes in the development, implementation and production of innovative, competitive and effective medicines, provides a full range of services in the pharmaceutical industry market in accordance with the requirements of GMP of Russia and EurAsEC.

NovaMedica Innotech has research and production equipment that allows solving the problems of modifying the pharmacological properties of drugs, changing their bioavailability and other properties of active substances or combining several active ingredients in one form, as well as carrying out their commercial production at their own facilities.

Business in Russia

2025: Sinmedex bought NovaMedica Innotech from Rusnano for ₽720 million

JSC "Sinmedex" acquired from the state-owned company "Rusnano" 100% of the shares of LLC "NovaMedica Innotech" for ₽720 million at the end of the auction. The transaction was completed on October 16, 2025, when Sinmedex became the sole owner of the pharmaceutical company.

According to Vedomosti, Rusnano announced a tender for the sale of the company in August 2025. Only one bid was submitted to bid. The starting price was ₽720 million, which became the total value of the transaction.

𝓲

Фото: Freepik

The representative of Rusnano did not disclose the identity of the buyer. The state-owned company plans to direct the funds received to the development of priority areas. Among them are projects of small-tonnage chemistry in accordance with the priorities of the national project "New Materials and Chemistry."

At the first stage, the projects relate to the creation of production of substances and raw materials for them - intermediates. It is also planned to produce active ingredients for chemical plant protection products.

JSC "Sinmedex" was registered in Moscow in July 2025. The founders of the company were not disclosed. The general director is a citizen of Belarus Nikolai Solodukha. Little is known about the company's activities.

A source familiar with the negotiations said that NovaMedica was interested in the Pharmeko group of Vladimir Babiy. The parties could not agree on the price for a long time. Vladimir Baby said that Sinmedex has nothing to do with Farmeko, and the NovaMedica group is not interested.

Senior partner of Verba Legal Alexander Panov said that NovaMedica Innotech was sold to an "independent investor in the field of pharmaceuticals." The company accompanied the deal. Panov did not name a specific partner.

NovaMedica Innotech is a production site and research center of the pharmaceutical company NovaMedica. The latter also includes NovaMedica LLC, which has a product portfolio of five registered drugs.^[1]

2022

Agreement with the Eurasian Academy of Good Practices on the exchange of knowledge and experience

NovaMedica Innotech will become the base for advanced training of specialists. the Russian pharmaceutical industries This was Rusnano reported on June 17, 2022.

The corresponding Memorandum of Cooperation was signed by R&D the center of the portfolio company NovaMedica and ANO.Eurasian Academy of Good Practices

The partners agreed to exchange knowledge and experience in the field of pharmaceutical development and contract production, as well as to hold joint training events at the NovaMedica Innotech R&D Center. In addition, cooperation involves the joint organization of congresses, conferences, round tables and seminars for the professional community, including with international participation.

In its educational activities, the Academy always applies an integrated approach in which theory and practice are harmoniously combined. Special network educational programs make it possible in the practical part of training to use not only simulation technologies, such as the VR plant, but also to consolidate the knowledge already gained on the basis of real pharmaceutical production that meets all GMP requirements. Our students master theory, while deeply immersing themselves in practice, learn to apply the knowledge gained and develop the necessary branches of competence, - said the executive director of the Eurasian Academy of Good Practices, Doctor of Pharmaceutical Sciences, Professor Irina Spichak.

I am glad that our cooperation will make the field of pharmaceutical development closer and more understandable for industry specialists. This is another step towards improving the quality of educational programs aimed at improving the professional level of pharmaceutical industry workers. Students of the Academy from all over the country will better learn about modern opportunities in the field of R&D, will gain real practical knowledge of the latest technologies and methods for the development and production of drugs. In the available format of master classes, they will be presented with specific technological solutions and real projects for scaling and planning production stages. Without a doubt, this will not only expand the horizons and increase the qualifications of specialists undergoing training, but will also bring to a new level the domestic manufacturers they represent, - commented Timofey Petrov, General Director of the R&D Center "NovaMedica Innotech."

Increase in production by 2 times

On May 12, 2022, Rusnano announced a doubling of the production capacity of the NovaMedica Innotech research and development center (part of NovaMedica, which in turn is a portfolio for Rusnano).

By May 2022, NovaMedica Innotech provides comprehensive services to 27 pharmaceutical companies - from drug development and registration to contract production. The center is simultaneously working on 55 projects. The capacity of the production site allows the production of up to 150 million medicinal units per year, including tablets, pelettes, soft and hard gelatin capsules.

Rusnano Pharmaceutical R&D Center doubles production

{{quote 'When Innoteh opened, the R&D market in Russia was just beginning to form. Most of our customers, whom we have been helping to develop new drugs for 5 years, were previously forced to seek help from European and American technology companies. Now they come to us, return again and recommend us to other market players, - said Timofey Petrov, General Director of NovaMedica Innotech, whose words are quoted by the Rusnano press service on May 12, 2022 }} According to Elena Litvinova, CEO of NovaMedik, the R&D center was conceived as a modern pharmaceutical hub specializing in the development of innovative dosage forms, which, in particular, allow improving the bioavailability and other properties of active substances. In addition, such developments can combine several active ingredients in one form so that drugs acquire new uses, as well as fundamentally superior to existing drugs in terms of efficacy and safety. Such drugs can be called improved generics or smart innovations.^[2]

2019: Localization of the production of the drug for normalizing sleep in Russia

On July 26, 2019, Unipharm announced that it had localized the production of a drug for normalizing sleep in Russia. According to the company, patients will be able to receive this medicine from a domestic manufacturer in 2020. Read more here.

Notes